Gilead Sciences' Descovy, or emtricitabine and tenofovir alafenamide, has gained FDA approval as the second option for pre-exposure HIV prophylaxis. The approval indicates the drug can be used to prevent the disease in transgender women and HIV-negative men who have sex with men but does not cover cisgender women.
Descovy approved as 2nd PrEP drug for HIV, with exclusions
Sign up for PCMA SmartBrief
Top news for PBMs
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.